Company
Natera
Natera has 13 drugs tracked on RxWires: 2 in Phase 3, 1 in Phase 2/3, 7 in Phase 2, 1 in Phase 1/2, 2 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Atezolizumab | Phase 3 | Colon Adenocarcinoma |
| Capecitabine | Phase 3 | Colorectal Cancer |
| Signatera test | Phase 2/3 | Stage III Colon Cancer |
| Discontinuation of the anti-HER2 maintenance therapy | Phase 2 | Metastatic Breast Cancer |
| Pembrolizumab & Enfortumab Vedotin (PEV) | Phase 2 | Urothelial Carcinoma |
| Pembrolizumab | Phase 2 | Hodgkin Lymphoma, Adult |
| Enfortumab vedotin | Phase 2 | Bladder Cancer |
| Tislelizumab | Phase 2 | Gastroesophageal Adenocarcinoma |
| Signatera ctDNA assay | Phase 2 | Metastatic Colorectal Cancer |
| Capivasertib | Phase 2 | Breast Cancer |
| CURATE.AI | Phase 1/2 | Solid Tumor |
| TAS-102 | Phase 1 | Colon Adenocarcinoma |
| Synthetic long peptide personalized cancer vaccine | Phase 1 | Muscle-Invasive Bladder Carcinoma |
Latest
Follow Natera on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.